8-K: IDEAYA Biosciences Secures Exclusive License for Novel Cancer Therapy, SHR-4849, from Hengrui Pharma

IDEAYA Biosciences has obtained an exclusive global license outside of Greater China to develop and commercialize SHR-4849, a promising DLL3-targeting antibody drug conjugate, from Hengrui Pharma.

Summary

• IDEAYA Biosciences has entered into a licensing agreement with Hengrui Pharma for the exclusive global rights, outside of Greater China, to develop and commercialize SHR-4849, a novel DLL3-targeting antibody drug conjugate.
• Hengrui Pharma is eligible to receive up to $1.045 billion in upfront and milestone payments, including a $75 million upfront fee, and royalties on net sales outside of Greater China.
• SHR-4849 is a Phase 1 asset that targets DLL3, which is highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), with expression rates of approximately 85% and 20-40%, respectively.
• Early clinical data from a Phase 1 trial in China shows promising results, with an overall response rate of approximately 73% in 11 evaluable SCLC patients at therapeutic dose levels.
• IDEAYA plans to file a US IND for SHR-4849 in the first half of 2025.
• The agreement does not change IDEAYA's previously guided cash runway of at least 2028.

Sentiment

Score: 8

Explanation: The document is very positive due to the promising early clinical data for SHR-4849 and the significant potential of the licensing agreement. The company's cash runway is also secure, which is a positive sign for investors.

Positives

• The licensing agreement provides IDEAYA with a promising clinical-stage asset with significant potential in SCLC and NETs.
• The early clinical data for SHR-4849 is very encouraging, showing a high response rate in SCLC patients.
• The deal aligns with IDEAYA's strategy to develop rational combinations of topo-payload based ADCs with their PARG inhibitor IDE161.
• The financial terms of the agreement include substantial potential milestone payments, which could provide significant future revenue.
• The agreement does not impact IDEAYA's cash runway, which is projected to extend to at least 2028.

Negatives

• The agreement requires significant upfront and potential milestone payments to Hengrui Pharma, totaling up to $1.045 billion.
• The success of SHR-4849 is still dependent on further clinical trials and regulatory approvals.
• The drug is still in early stages of development, and there are inherent risks associated with drug development.

Risks

• The development of SHR-4849 is subject to the uncertainties inherent in the drug development process, including clinical trial design and regulatory approvals.
• There is a risk that the drug may not achieve the same level of efficacy or safety in larger clinical trials.
• The company faces challenges associated with manufacturing drug products and protecting its intellectual property.
• The company's ability to fund operations is dependent on its existing cash reserves and future financing.

Future Outlook

IDEAYA plans to file a US IND for SHR-4849 in the first half of 2025 and will continue to develop the drug for potential use in SCLC and NETs, with a focus on rational combinations with their PARG inhibitor IDE161. The company's cash runway is projected to extend to at least 2028.

Management Comments

• Yujiro S. Hata, CEO of IDEAYA, stated that SHR-4849 is competitively well positioned with first-in-class potential in the DLL3 topo-I-payload ADC field.
• Daniel A. Simon, Chief Business Officer of IDEAYA, noted that SHR-4849 accelerates IDEAYA's strategic objective to develop rational clinical combinations of topo-payload based ADCs with their PARG inhibitor IDE161.
• Frank Jiang, Chief Strategy Officer and Board Director of Hengrui Pharma, said that SHR-4849 is a novel DLL3 targeting ADC showing encouraging early clinical signals in small-cell lung cancer with a manageable safety profile.

Industry Context

This announcement highlights the growing interest in antibody-drug conjugates (ADCs) as a targeted therapy for cancer, particularly in areas with high unmet medical needs such as SCLC and NETs. The deal also reflects the increasing collaboration between Western and Chinese pharmaceutical companies to develop and commercialize innovative therapies.

Comparison to Industry Standards

• The 73% overall response rate in SCLC patients observed in the Phase 1 trial of SHR-4849 is very promising compared to other therapies in this space, such as standard chemotherapy which typically has response rates in the 20-30% range.
• Other companies developing DLL3-targeting therapies include AbbVie with their Rova-T, which has shown mixed results in clinical trials, and Amgen with their Tarlatamab, which has shown promising results in SCLC.
• The licensing agreement between IDEAYA and Hengrui Pharma is similar to other deals in the biotech industry, where companies acquire rights to develop and commercialize promising drug candidates from other companies.

Stakeholder Impact

• Shareholders will likely view this agreement positively due to the potential for future revenue and the promising clinical data.
• Employees may benefit from the company's growth and expansion.
• Patients with SCLC and NETs may benefit from the development of a new treatment option.
• Hengrui Pharma will receive significant upfront and potential milestone payments, as well as royalties on net sales.

Next Steps

• IDEAYA will file a US IND for SHR-4849 in the first half of 2025.
• IDEAYA will continue to develop SHR-4849 for potential use in SCLC and NETs.
• IDEAYA will explore rational combinations of SHR-4849 with their PARG inhibitor IDE161.

Key Dates

Keywords

IDEAYA Biosciences, Hengrui Pharma, SHR-4849, DLL3, Antibody Drug Conjugate, ADC, Small Cell Lung Cancer, SCLC, Neuroendocrine Tumors, NETs, License Agreement, Oncology, Precision Medicine, Clinical Trial, IND Filing